Dora Richardson

Dora Nellie Richardson (June 1, 1919- September 15, 1998) was a British organic chemist, known for first synthesizing Tamoxifen (ICI-46,474), a groundbreaking targeted therapy for hormone-sensitive breast cancer, in England in 1962. Her research marked a turning point in oncology. Tamoxifen's ability to selectively block estrogen receptors revolutionized breast cancer treatment by offering a more precise and less toxic alternative to traditional chemotherapy. Richardson was named on several patents.

Early life and education Richardson was born in Wimbledon, South London, in 1919. She was one of the few women in her program and excluded from societies and networks that could have supported her early career development. However, early studies showed that rather than suppress ovulation, tamoxifen stimulated it, making it unsuitable as a contraceptive.

Despite this, Richardson's early work in synthesizing and refining tamoxifen was fundamental to its eventual success. Unfortunately that document remained largely hidden amongst the company’s archives. Today, tamoxifen remains one of the world's most widely prescribed breast cancer treatments.

Personal life Richardson enjoyed gardening, needlework, and the companionship of a pet parakeet. She was a lifelong Protestant and a founding member of her local Soroptimist Club, an organization dedicated to empowering women through education. Richardson died in 1998.